中医药调控肠道菌群防治炎症性肠病的研究进展*

doi:10.3870/j.issn.1672-0741.25.11.016

摘要/Abstract

摘要： 炎症性肠病是一种慢性非特异性炎症性疾病,其病因及发病机制尚不明确,治疗方面也存在很多难点,曾被称为“绿色癌症”,患者需长期乃至终身治疗,为个人及社会带来沉重负担。中医药在治疗炎症性肠病中有着确切疗效和独特优势。近年来,众多研究揭示肠道菌群在炎症性肠病的发生发展过程中起着关键作用。该文旨在综述肠道菌群和炎症性肠病之间的相互作用,并从调节肠道菌群角度探讨中医药防治炎症性肠病的研究现状,以期为临床治疗炎症性肠病提供新的思路和策略,使中医药在未来炎症性肠病治疗和新药物研发中发挥更大作用。

关键词: 炎症性肠病, 肠道菌群, 中医药

Abstract: Inflammatory bowel disease(IBD)is a chronic non-specific inflammatory condition of unknown etiology and poorly understood pathogenesis.Its treatment remains challenging,and the disease was once termed “green cancer”.Patients require long-term or even lifelong treatment,which imposes a substantial burden on both individuals and society.Traditional Chinese medicine has demonstrated efficacy and unique advantages in treating IBD.In recent years,numerous studies have revealed that the gut microbiota plays a key role in the development and progression of IBD.This article reviews the interactions between the gut microbiota and IBD,and explores the current state of research on traditional Chinese medicine for the prevention and treatment of IBD from the perspective of regulating the gut microbiota.We aim to provide new therapeutic ideas and strategies for the clinical management of IBD,and to enable traditional Chinese medicine to play a greater role in future therapeutic strategies and drug development for this disease.

Key words: inflammatory bowel disease, gut microbiota, traditional Chinese medicine

中图分类号:

R574.62
R259

梅婷雨, 唐迎春. 中医药调控肠道菌群防治炎症性肠病的研究进展^*[J]. 华中科技大学学报（医学版）, 2026, 55(2): 271-277.

Mei Tingyu, Tang Yingchun. Research Progress on Regulating Gut Microbiota with Traditional Chinese Medicine for the Prevention and Treatment of Inflammatory Bowel Disease[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2026, 55(2): 271-277.

参考文献

[1] Zhao M,Gönczi L,Lakatos P L,et al.The burden of inflammatory bowel disease in Europe in 2020[J].J Crohns Colitis,2021,15(9):1573-1587.
[2] Yang H,Qian J.Epidemiological research,burden,and clinical advances of inflammatory bowel disease in China[J].Chin Med J,2024,137(9):1009-1011.
[3] Guan Q.A comprehensive review and update on the pathogenesis of inflammatory bowel disease[J].J Immunol Res,2019,2019:7247238.
[4] 孔冰慧,白龙洲,杨丽.肠道菌群与微小RNA在炎症性肠病中相互作用关系研究进展[J].中国比较医学杂志,2024,34(5):169-178.
Kong B H,Bai L Z,Yang L.Research progress on the interaction between gut microbiota and microRNA in inflammatory bowel disease[J].Chinese Journal of Comparative Medicine,2024,34(5):169-178.
[5] Gomaa E Z.Human gut microbiota/microbiome in health and diseases:A review[J].Antonie Van Leeuwenhoek,2020,113(12):2019-2040.
[6] Qiu P,Ishimoto T,Fu L,et al.The gut microbiota in inflammatory bowel disease[J].Front Cell Infect Microbiol,2022,12:733992.
[7] Lloyd-Price J,Arze C,Ananthakrishnan A N,et al.Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases[J].Nature,2019,569(7758):655-662.
[8] Imhann F,Vich Vila A,Bonder M J,et al.Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease[J].Gut,2018,67(1):108-119.
[9] Kostic A D,Xavier R J,Gevers D.The microbiome in inflammatory bowel disease:Current status and the future ahead[J].Gastroenterology,2014,146(6):1489-1499.
[10] Li J,Butcher J,Mack D,et al.Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease[J].Inflamm Bowel Dis,2015,21(1):139-153.
[11] 蔡尚党,陈建设,娄宁,等.炎症性肠病患者肠道菌群结构变化与炎性指标的关系研究[J].中华医院感染学杂志,2016,26(9):1942-1945.
Cai S D,Chen J S,Lou N,et al.Relationship between changes of intestinal microflora and inflammatory indexes in patients with inflammatory bowel diseases[J].Chinese Journal of Nosocomiology,2016,26(9):1942-1945.
[12] Prosberg M,Bendtsen F,Vind I,et al.The association between the gut microbiota and the inflammatory bowel disease activity:A systematic review and meta-analysis[J].Scand J Gastroenterol,2016,51(12):1407-1415.
[13] Hu Y,Chen Z,Xu C,et al.Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel disease[J].Nutrients,2022,14(23):5140.
[14] Anderson C J,Medina C B,Barron B J,et al.Microbes exploit death-induced nutrient release by gut epithelial cells[J].Nature,2021,596(7871):262-267.
[15] Martin-Gallausiaux C,Marinelli L,Blottière H M,et al.SCFA:Mechanisms and functional importance in the gut[J].Proc Nutr Soc,2021,80(1):37-49.
[16] Khan S,Waliullah S,Godfrey V,et al.Dietary simple sugars alter microbial ecology in the gut and promote colitis in mice[J].Sci Transl Med,2020,12(567):eaay6218.
[17] Liang L,Liu L,Zhou W,et al.Gut microbiota-derived butyrate regulates gut mucus barrier repair by activating the macrophage/WNT/ERK signaling pathway[J].Clin Sci,2022,136(4):291-307.
[18] Jalanka J,Cheng J,Hiippala K,et al.Colonic mucosal microbiota and association of bacterial taxa with the expression of host antimicrobial peptides in pediatric ulcerative colitis[J].Int J Mol Sci,2020,21(17):6044.
[19] 杨紫瑜,李敏.肠道菌群失调在炎症性肠病发生发展中的作用及防控策略[J].中华预防医学杂志,2022,56(9):1175-1181.
Yang Z Y,Li M.The role of gut microbiota dysbiosis in the occurrence and development of inflammatory bowel disease and its prevention and control strategies[J].Chinese Journal of Preventive Medicine,2022,56(9):1175-1181.
[20] 李思慧,吴巧凤.肠道菌群对Th17/Treg免疫平衡和炎症性肠病影响的研究进展[J].免疫学杂志,2019,35(8):722-726.
Li S H,Wu Q F.The progress of the roles of gut flora in Thl7/Treg axis balance and inflammatory bowel diseases[J].Immunological Journal,2019,35(8):722-726.
[21] Hang S,Paik D,Yao L,et al.Bile acid metabolites control T(H)₁₇ and T(reg)cell differentiation[J].Nature,2019,576(7785):143-148.
[22] Gadaleta R M,van Erpecum K J,Oldenburg B,et al.Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease[J].Gut,2011,60(4):463-472.
[23] Zheng L,Wen X L.Gut microbiota and inflammatory bowel disease:The current status and perspectives[J].World J Clin Cases,2021,9(2):321-333.
[24] An D,Oh S F,Olszak T,et al.Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells[J].Cell,2014,156(1/2):123-133.
[25] Ding N S,McDonald J A K,Perdones-Montero A,et al.Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn's disease[J].J Crohns Colitis,2020,14(8):1090-1102.
[26] Hosseinkhani F,Heinken A,Thiele I,et al.The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases[J].Gut Microbes,2021,13(1):1882927.
[27] Gasaly N,de Vos P,Hermoso M A.Impact of bacterial metabolites on gut barrier function and host immunity:A focus on bacterial metabolism and its relevance for intestinal inflammation[J].Front Immunol,2021,12:658354.
[28] Sun M,Ma N,He T,et al.Tryptophan(Trp)modulates gut homeostasis via aryl hydrocarbon receptor(AhR)[J].Crit Rev Food Sci Nutr,2020,60(10):1760-1768.
[29] 文娜,黄超群,胡运莲.基于中医病性探讨溃疡性结肠炎与肠道菌群关系以及粪菌寒热属性[J].中医药导报,2025,31(1):153-157,168.
Wen N,Huang C Q,Hu Y L.Discussion on the relationship between ulcerative colitis and intestinal flora and the cold and heat properties of fecal bacteria based on the disease characteristics of traditional Chinese medicine[J].Guiding Journal of Traditional Chinese Medicine and Pharmacology,2025,31(1):153-157,168.
[30] 王春霞,葛俊李,李芳,等.中药治疗溃疡性结肠炎作用及机制研究进展[J].中国实验方剂学杂志,2023,29(2):270-282.
Wang C X,Ge J L,Li F,et al.Effect and mechanism of traditional Chinese medicine in treatment of ulcerative colitis:A review[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(2):270-282.
[31] 中华中医药学会脾胃病分会,李军祥,唐旭东.溃疡性结肠炎中医诊疗专家共识(2023)[J].中华中医药杂志,2024,39(1):288-296.
Branch of Spleen and Stomach Diseases,China Association of Chinese Medicine,Li J X,Tang X D.Experts consensus on traditional Chinese medicine diagnosis and treatment of ulcerative colitis(2023)[J].China Journal of Traditional Chinese Medicine and Pharmacy,2024,39(1):288-296.
[32] Su D,Liao Z,Feng B,et al.Pulsatilla chinensis saponins cause liver injury through interfering ceramide/sphingomyelin balance that promotes lipid metabolism dysregulation and apoptosis[J].Phytomedicine,2020,76:153265.
[33] Liu Y,Zhou M,Yang M,et al.Pulsatilla chinensis saponins ameliorate inflammation and DSS-induced ulcerative colitis in rats by regulating the composition and diversity of intestinal flora[J].Front Cell Infect Microbiol,2021,11:728929.
[34] 王一帆,王凤云,张佳琪,等.中医药调节肠道菌群防治溃疡性结肠炎的研究进展[J].中华中医药学刊,2021,39(9):160-164.
Wang Y F,Wang F Y,Zhang J Q,et al.Research advances on regulation of intestinal flora by traditional Chinese medicine in prevention and treatment of ulcerative colitis[J].Chinese Archives of Traditional Chinese Medicine,2021,39(9):160-164.
[35] Dong Y,Fan H,Zhang Z,et al.Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt/β-catenin pathway[J].Int J Biol Sci,2022,18(4):1381-1397.
[36] 黄宇哲,吴前震,许腾龙,等.多糖对炎症性疾病及肠道菌群调控作用的研究进展[J].中国药理学通报,2022,38(11):1601-1606.
Huang Y Z,Wu Q Z,Xu T L,et al.Advances in research of polysaccharides on inflammatory diseases and gut microbiota[J].Chinese Pharmacological Bulletin,2022,38(11):1601-1606.
[37] Wan L,Qian C,Yang C,et al.Ginseng polysaccharides ameliorate ulcerative colitis via regulating gut microbiota and tryptophan metabolism[J].Int J Biol Macromol,2024,265(Pt 2):130822.
[38] 秦艳琴,韦熔煌,梁雅琳,等.雷公藤多苷治疗溃疡性结肠炎的作用机制研究进展[J].广西医学,2023,45(5):592-595.
Qin Y Q,Wei R H,Liang Y L,et al.Mechanism of Tripterygium glycosides in the treatment of ulcerative colitis:A research progress[J].Guangxi Medical Journal,2023,45(5):592-595.
[39] Li M,Guo W,Dong Y,et al.Beneficial effects of celastrol on immune balance by modulating gut microbiota in experimental ulcerative colitis mice[J].Genomics Proteomics Bioinformatics,2022,20(2):288-303.
[40] Li W,Ding J,Chen S,et al.Alleviation of colitis by honeysuckle MIR2911 via direct regulation of gut microbiota[J].J Control Release,2024,376:123-137.
[41] Jiang S,Li H,Zhang L,et al.Generic Diagramming Platform(GDP):A comprehensive database of high-quality biomedical graphics[J].Nucleic Acids Res,2025,53(D1):D1670-D1676.
[42] 戴丽蓉,陈启明,刘喜平,等.半夏泻心汤及其拆方对菌群紊乱幼鼠结肠黏膜免疫的影响[J].中国实验方剂学杂志,2022,28(11):42-50.
Dai L R,Chen Q M,Liu X P,et al.Banxia Xiexintang and its disassembled prescriptions regulate colonic mucosal immunity in young rats with flora disorder[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(11):42-50.
[43] 陈健,张梁坤,谷文超,等.半夏泻心汤对右旋葡聚糖硫酸钠诱导的溃疡性结肠炎小鼠肠道菌群的影响[J].中国中药杂志,2021,46(11):2871-2880.
Chen J,Zhang L K,Gu W C,et al.Effect of Banxia Xiexin decoction on intestinal flora of mice with ulcerative colitis induced by dextran sodium sulfate[J].China Journal of Chinese Materia Medica,2021,46(11):2871-2880.
[44] Luo Y,Fu S,Liu Y,et al.Banxia Xiexin decoction modulates gut microbiota and gut microbiota metabolism to alleviate DSS-induced ulcerative colitis[J].J Ethnopharmacol,2024,326:117990.
[45] 荣耀军,古韶东,张贵育,等.基于LC-MS联用技术和网络药理学探讨芍药汤调控肠道菌群防治大肠癌的活性成分及作用机制[J].中医药导报,2023,29(9):144-150.
Rong Y J,Gu S D,Zhang G Y,et al.Exploring the active ingredients and mechanism of Shaoyao decoction to regulate intestinal flora against colorectal cancer based on LC-MS coupling technique and network pharmacology[J].Guiding Journal of Traditional Chinese Medicine and Pharmacology,2023,29(9):144-150.
[46] Zhang Y,Han L,Dong J,et al.Shaoyao decoction improves damp-heat colitis by activating the AHR/IL-22/STAT3 pathway through tryptophan metabolism driven by gut microbiota[J].J Ethnopharmacol,2024,326:117874.
[47] Lin Z,Wang J,Luo H,et al.Changdiqing decoction(CDQD)ameliorates colitis via suppressing inflammatory macrophage activation and modulating gut microbiota[J].Phytomedicine,2025,143:156856.
[48] 龙鑫月,弓艳霞,唐艳萍.葛根芩连汤加减联合美沙拉嗪治疗大肠湿热型溃疡性结肠炎临床效果及其对肠道菌群、免疫功能和炎症水平的调节[J].中华中医药学刊,2024,42(1):118-121.
Long X Y,Gong Y X,Tang Y P.Clinical effect of Gegen Qinlian decoction combined with mesalazine in treatment of damp-heat ulcerative colitis of large intestine and its regulation of intestinal flora,immune function and inflammation[J].Chinese Archives of Traditional Chinese Medicine,2024,42(1):118-121.
[49] 包春辉,钟捷,刘慧荣,等.针灸对活动期克罗恩病患者负性情绪及血浆色氨酸代谢的影响[J].中国针灸,2021,41(1):17-22.
Bao C H,Zhong J,Liu H R,et al.Effect of acupuncture-moxibustion on negative emotions and plasma tryptophan metabolism in patients with Crohn's disease at active stage[J].Chinese Acupuncture & Moxibustion,2021,41(1):17-22.
[50] 高乐女,钟兵,王勇.基于扶正祛邪探讨针灸疗法对肠道菌群的影响[J].中医杂志,2018,59(14):1252-1254.
Gao L N,Zhong B,Wang Y.Effects of acupuncture therapy on intestinal microbiota:Based on strengthening vital qi to eliminate pathogenic factor[J].Journal of Traditional Chinese Medicine,2018,59(14):1252-1254.
[51] 张新鹭.电针“天枢”、“足三里”对DSS诱导的UC大鼠肠道菌群失调干预作用的研究[D].沈阳:辽宁中医药大学,2021.
Zhang X L.Study on the intervention effect of electroacupuncture at“Tianshu”(ST25)and“Zusanli”(ST36)on intestinal flora dysbiosis in DSS-induced UC rats[D].Shenyang:Liaoning University of Traditional Chinese Medicine,2021.
[52] Liu G H,Liu H M,Chen Y S,et al.Effect of electroacupuncture in mice with dextran sulfate sodium-induced colitis and the influence of gut microbiota[J].Evid Based Complement Alternat Med,2020,2020:2087903.
[53] Yang Y,Pang F,Zhou M,et al.Electroacupuncture reduces inflammatory bowel disease in obese mice by activating the Nrf2/HO-1 signaling pathways and repairing the intestinal barrier[J].Diabetes Metab Syndr Obes,2024,17:435-452.
[54] Bao C,Wu L,Wang D,et al.Acupuncture improves the symptoms,intestinal microbiota,and inflammation of patients with mild to moderate Crohn's disease:A randomized controlled trial[J].EClinicalMedicine,2022,45:101300.

中医药调控肠道菌群防治炎症性肠病的研究进展^*

Research Progress on Regulating Gut Microbiota with Traditional Chinese Medicine for the Prevention and Treatment of Inflammatory Bowel Disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	朱梦瑶, 张瑶. 肠道菌群在糖尿病心肌病中的作用研究进展^*[J]. 华中科技大学学报（医学版）, 2026, 55(2): 278-283.
[2]	阎瑾逸, 李志军. 肠道微生态与神经系统自身免疫性疾病[J]. 华中科技大学学报（医学版）, 2024, 53(4): 539-453.
[3]	孟雅楠, 张玉伟, 张馨月, 刘晋芳, 苗宇船. 逍遥散调节非酒精性脂肪性肝炎模型大鼠肠道菌群的研究[J]. 华中科技大学学报（医学版）, 2023, 52(4): 517-524.
[4]	高珊, 杨镭镭, 施媛, 夏艳琼, 彭坚. 饮食添加益生元菊粉改善烧伤大鼠肠道菌群紊乱和骨骼肌分解代谢[J]. 华中科技大学学报（医学版）, 2023, 52(1): 60-67.
[5]	黄晓颖, 黄启友, 谢竹夫, 姚菲, 龙辉, 吴清明. 二甲双胍对2型糖尿病大鼠结直肠癌发生率及其肠道菌群的影响[J]. 华中科技大学学报（医学版）, 2022, 51(3): 317-325.